Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

66.40 +0.77 (+1.17%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
59 60 Next >
The 7 Best Mutual Funds to Invest in for May 2023
With rising uncertainties in the economy and the capital markets, investors have an incentive to consider the best mutual funds. 
Via InvestorPlace
WHO Ends Global Emergency Status for COVID-19 3 Years After Declaration, CDC Director Resigns
The World Health Organization ended the global emergency 
Via Benzinga
GSK: Add This Cheap Chip Play To Your Portfolio
GSK pays a decent quarterly dividend. The latest declared dividend is $0.35 per share, giving GSK a yield of 3.85%. 
Via Talk Markets
3 Low-Volatility Stocks for a Stable Investment Strategy
These are the low-volatility stocks to buy for high total returns as they represent attractively-valued dividend names. 
Via InvestorPlace
$1000 Invested In This Stock 15 Years Ago Would Be Worth $3,700 Today
Via Benzinga
AstraZeneca Plc (AZN) Q1 2023 Earnings Call Transcript
AZN earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Earnings Outlook For AstraZeneca
Via Benzinga
AstraZeneca PLC (NASDAQ: AZN) Records 52-Week High Friday Morning
Via Investor Brand Network
High-Yield Pfizer Falls Off The COVID Cliff, And Survives
Pfizer is a value and high-yield compared to its peers and it it outperforming expectations in 2023; The pipeline is robust. 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
FDA Advisory Committee Votes Favoring Restricted Use Of AstraZeneca/Merck's Prostate Cancer Drug
Via Benzinga
FDA Casts Doubt on Merck/AstraZeneca's Cancer Drug for Prostate Cancer Ahead of Adcomm Meeting
The FDA's Oncologic Drugs Advisory Committee will be meeting tomorrow, Friday, 28 April, to discuss the supplemental new drug application (sNDA) for Lynparza (olaparib) in combination with abiraterone... 
Via Benzinga
AstraZeneca's COVID-19 Vaccine Loses Shine, Cancer Drug Imfinzi & Emerging Markets Stabilize Q1 Revenues
AstraZeneca Plc (NASDAQ: AZN) has reported Q1 FY23 core EPS of $1.92, up 1% Y/Y (+6% on constant currency), better than the consensus of $1.07. The company clocked Q1 sales of $10.88 billion, -4% (flat... 
Via Benzinga
7 Low-Risk Stocks to Buy if You Only Want to Beat Inflation
Getting in on some low-risk stocks is a good idea if you want to preserve your capital during inflation and before the upcoming recession. 
Via InvestorPlace
A Look Into AstraZeneca's Debt
Via Benzinga
Price Over Earnings Overview: AstraZeneca
Via Benzinga
AstraZeneca PLC (NASDAQ: AZN) Records 52-Week High Tuesday Morning
Via Investor Brand Network
Artelo Enters Next Phase Of Evaluation Of Its Cannabinoid Receptor Targeting Drug For The Treatment Of Cancer-Related Anorexia And Weight Loss
Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and... 
Via Benzinga
AstraZeneca, Ionis Unveil Complete Phase 3 Data For ATTR Candidate, Says Drug Halts Disease Progression
Via Benzinga
NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks
From AstraZeneca
Via Business Wire
Could This Rare-Disease Drug Candidate Become a Blockbuster?
This drug candidate could be a great treatment option for patients with a potentially deadly disease. 
Via The Motley Fool
Why AstraZeneca Shares Are Trading Higher Today?
AstraZeneca plc's (NASDAQ: AZN) vaccine head highlighted the confidence that the company's new COVID-19 antibody treatment could protect immunocompromised patients against all known virus variants. 
Via Benzinga
Here's How Much $1000 Invested In AstraZeneca 5 Years Ago Would Be Worth Today
Via Benzinga
AstraZeneca Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
Argus Research Maintains Buy Rating for AstraZeneca: Here's What You Need To Know
Via Benzinga
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide. 
Via Benzinga
IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial
From AstraZeneca
Via Business Wire
3 Healthcare Dividend Payers With Big Price Growth
Sanofi, AstraZeneca and Smith & Nephew all boast price performance better than about 80% of the broader market, and all are dividend payers. 
Via MarketBeat
AstraZeneca PLC (NASDAQ: AZN) Sets New 52-Week High in Wednesday Session
Via Investor Brand Network
$1000 Invested In AstraZeneca 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Biden Administration Launches $5B Program To Boost Development Of Pan-Coronavirus Vaccine, Treatments
The White House plans to devote $5 billion to develop effective treatments and vaccines against current and future Covid variants, a Department of Health and Human Services (HHS) spokesperson and a... 
Via Benzinga
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS